Lupin recieves USFDA nod to market generic anthelmintic tablets

Shares of Lupin closed at Rs 920.45 per scrip on the BSE
Drug firm Lupin on Thursday said it had received an approval from the US health regulator to market its generic anthelmintic Albendazole tablets.

The company has received approval to market its Albendazole tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The product is a generic version of Impax Laboratories Inc's Albenzatablets in the same strength, it added.

According to IQVIA MAT April 2020 data, Albendazole tablets had an annual sales of around $34 million in the US, Lupin said.

"The tablets are indicated for treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm," it added.

Shares of Lupin closed at Rs 920.45per scrip on the BSE, down 0.88per cent over previous close.


Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel